Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based psychiatric benefits—a critical review. Pharmacopsychiatry. 2024;57:115–32.

Article  PubMed  Google Scholar 

Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: adverse outcomes and self-reported impact of cannabis use by mental health status: substance use & misuse. Subst Use Misuse. 2022;57:719–29.

Article  PubMed  Google Scholar 

Hasin D, Walsh C. Cannabis use, cannabis use disorder, and comorbid psychiatric illness: a narrative review. J Clin Med. 2020;10:15.

Article  PubMed  PubMed Central  Google Scholar 

Kuhns L, Kroon E, Colyer-Patel K, Cousijn J. Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence. Psychopharmacology. 2022;239:1231–49.

Article  CAS  PubMed  Google Scholar 

Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382: e072348.

Article  PubMed  PubMed Central  Google Scholar 

Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, et al. Major phytocannabinoids and their related compounds: should we only search for drugs that act on cannabinoid receptors? Pharmaceutics. 2021;13:1823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, et al. Important flavonoids and their role as a therapeutic agent [Internet]. Molecules; 2020. https://www.ncbi.nlm.nih.gov/pubmed/33187049.

Dahlgren MK, Kosereisoglu D, Sagar KA, Smith RT, El-Abboud C, Lambros AM, et al. A national survey study of cannabis use during menopause: identifying variables associated with recreational, medical, and hybrid use. J Stud Alcohol Drugs. 2024. https://doi.org/10.15288/jsad.24-00014.

Article  PubMed  Google Scholar 

Donnan J, Shogan O, Bishop L, Swab M, Najafizada M. Characteristics that influence purchase choice for cannabis products: a systematic review. J Cannabis Res. 2022;4:9.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Romeu A, Elmore J, Mayhugh RE, Schlienz NJ, Martin EL, Strickland JC, et al. Online survey of medicinal cannabis users: qualitative analysis of patient-level data. Front Pharmacol [Internet]. 2022 [cited 2024 Sep 12];13. https://doi.org/10.3389/fphar.2022.965535/full.

Kritikos AF, Pacula RL. Characterization of cannabis products purchased for medical use in New York State. JAMA Netw Open. 2022;5: e2227735.

Article  PubMed  PubMed Central  Google Scholar 

Lambros AM, Sagar KA, Dahlgren MK, Kosereisoglu D, El-Abboud C, Smith RT, et al. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure. Sci Rep. 2023;13: 5869.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright M, Di Ciano P, Brands B. Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5:191–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:51–64.

Article  CAS  PubMed  Google Scholar 

Gururajan A, Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 2016;176:281–90.

Article  PubMed  Google Scholar 

Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019;9:2045125319881916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12: 777804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13: e0195687.

Article  PubMed  PubMed Central  Google Scholar 

Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, et al. Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat. 2020;77:1044–51.

Article  Google Scholar 

Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.

Article  PubMed  PubMed Central  Google Scholar 

Weiser M, Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci. 2005;7:81–5.

Article  PubMed  PubMed Central  Google Scholar 

Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79:549–56.

Article  PubMed  Google Scholar 

Hamilton I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction. 2017;112:1653–7.

Article  PubMed  Google Scholar 

Farris MS, Shakeel MK, Addington J. Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. Soc Psychiatry Psychiatr Epidemiol. 2020;55:527–37.

Article  PubMed  Google Scholar 

Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18:12.

Article  PubMed  Google Scholar 

van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 2013;8: e76690.

Article  PubMed  PubMed Central  Google Scholar 

Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269:107–20.

Article  PubMed  Google Scholar 

Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status. Addict Behav. 2021;121: 106991.

Article  PubMed  Google Scholar 

Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res. 2022;308: 114347.

Article  CAS  PubMed  Google Scholar 

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.

Anxiety disorders [Internet] [cited 2024 Sep 12]. https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders.

Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17:327–35.

Article  PubMed  PubMed Central  Google Scholar 

Hudson A, Hudson P. Risk factors for cannabis-related mental health harms in older adults: a review. Clin Gerontol. 2021;44:3–15.

Article  PubMed  Google Scholar 

Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29.

Article  PubMed